Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy

被引：36

作者：

Filippi, Andrea Riccardo ^{[1
]}

Botticella, Angela ^{[1
]}

Bello, Marilena ^{[2
]}

Botto, Barbara ^{[2
]}

Castiglione, Anna ^{[2
,3
]}

Gavarotti, Paolo ^{[2
]}

Gottardi, Daniela ^{[4
]}

Parvis, Guido ^{[5
]}

Bisi, Gianni ^{[2
]}

Levis, Alessandro ^{[6
]}

Vitolo, Umberto ^{[2
]}

Ricardi, Umberto ^{[1
]}

机构：

[1] Univ Turin, Dept Oncol, Radiat Oncol Unit, I-10126 Turin, Italy

[2] Univ Turin, I-10126 Turin, Italy

[3] Univ Turin, S Giovanni Battista Hosp, CPO Piemonte, I-10126 Turin, Italy

[4] Univ Turin, Molinette Mauriziano Hosp, I-10126 Turin, Italy

[5] Univ Turin, S Luigi Hosp, Orbassano, Italy

[6] SS Antonio & Biagio Hosp, Alessandria, Italy

来源：

LEUKEMIA & LYMPHOMA | 2013年 / 54卷 / 06期

关键词：

Hodgkin lymphoma; prognostic factors; involved-field radiotherapy; PET; response-adapted therapy; INVOLVED-FIELD; FREE SURVIVAL; PET SCAN; CYCLES; FDG-PET; CHEMOTHERAPY; DISEASE;

D O I：

10.3109/10428194.2012.735667

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of the study was to investigate whether interim positron emission tomography (iPET) is prognostic in a cohort of patients with early stage Hodgkin lymphoma (HL) homogeneously treated with 3-4 cycles of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) followed by 30 Gy involved field radiotherapy. Eighty patients were selected (stage I-IIA HL, availability of iPET, minimum follow-up of 12 months), and after central review, 70 were judged negative (iPET - : 87.5%) and 10 positive (iPET+ : 12.5%). The two groups were then analyzed for response, progression-free survival (PFS) and overall survival (OS). Only one out of 70 iPET - patients relapsed, with 69 in continuous complete remission (CCR). All 10 iPET+ patients achieved a complete response and maintained persistent CCR at follow-up. The 3-year PFS and OS were, respectively, 97% and 98.4% for iPET- and 100% and 100% for iPET+ (p = 0.63). iPET positivity does not seem to be a significant prognostic factor, and change in therapeutic strategy on the basis of iPET does not appear currently advisable outside clinical trials.

引用

页码：1183 / 1187

页数：5

共 12 条

[1] End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma [J].

Barnes, J. A. ;

LaCasce, A. S. ;

Zukotynski, K. ;

Israel, D. ;

Feng, Y. ;

Neuberg, D. ;

Toomey, C. E. ;

Hochberg, E. P. ;

Canellos, G. P. ;

Abramson, J. S. .

ANNALS OF ONCOLOGY, 2011, 22 (04) :910-915

[2] 18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma [J].

Cerci, Juliano J. ;

Pracchia, Luis F. ;

Linardi, Camila C. G. ;

Pitella, Felipe A. ;

Delbeke, Dominique ;

Izaki, Marisa ;

Trindade, Evelinda ;

Soares Junior, Jose ;

Buccheri, Valeria ;

Meneghetti, Jose C. .

JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) :1337-1343

[3] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[4] Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study [J].

Gallamini, Andrea ;

Hutchings, Martin ;

Rigacci, Luigi ;

Specht, Lena ;

Merli, Francesco ;

Hansen, Mads ;

Patti, Caterina ;

Loft, Annika ;

Di Raimondo, Francesco ;

D'Amore, Francesco ;

Biggi, Alberto ;

Vitolo, Umberto ;

Stelitano, Caterina ;

Sancetta, Rosario ;

Trentin, Livio ;

Luminari, Stefano ;

Iannitto, Emilio ;

Viviani, Simonetta ;

Pierri, Ivana ;

Levis, Alessandro .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) :3746-3752

[5] Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma [J].

Hutchings, M ;

Mikhaeel, NG ;

Fields, PA ;

Nunan, T ;

Timothy, AR .

ANNALS OF ONCOLOGY, 2005, 16 (07) :1160-1168

[6] FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma [J].

Hutchings, M ;

Loft, A ;

Hansen, M ;

Pedersen, LM ;

Buhl, T ;

Jurlander, J ;

Buus, S ;

Keiding, S ;

D'Amore, F ;

Boesen, AM ;

Berthelsen, AK ;

Specht, L .

BLOOD, 2006, 107 (01) :52-59

[7] REPORT OF A COMMITTEE CONVENED TO DISCUSS THE EVALUATION AND STAGING OF PATIENTS WITH HODGKINS-DISEASE - COTSWOLDS MEETING [J].

LISTER, TA ;

CROWTHER, D ;

SUTCLIFFE, SB ;

GLATSTEIN, E ;

CANELLOS, GP ;

YOUNG, RC ;

ROSENBERG, SA ;

COLTMAN, CA ;

TUBIANA, M .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1630-1636

[8] Report on the First International Workshop on interim-PET scan in lymphoma [J].

Meignan, Michel ;

Gallamini, Andrea ;

Haioun, Corinne .

LEUKEMIA & LYMPHOMA, 2009, 50 (08) :1257-1260

[9] Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy [J].

Sher, D. J. ;

Mauch, P. M. ;

Van Den Abbeele, A. ;

LaCasce, A. S. ;

Czerminski, J. ;

Ng, A. K. .

ANNALS OF ONCOLOGY, 2009, 20 (11) :1848-1853

[10]

TUBIANA M, 1989, BLOOD, V73, P47

← 1 2 →